PNV - Banter and General Comments, page-10636

The biggest driver of sales of medical specialist aids is adoption by the specialists who use them, and their promotion and dissemination of experiences and data they release. The increase in sales of the company year on year at an accelerating pace reflects this adoption and the increasing information disseminated. Alongside this exciting growth in sales and goodwill earlier hesitations of adoption due to analyst bias towards other competitors using organic products has been significantly eroded as widespread acknowledgement of the superiority of the product over these with lower infection risks resulting in cheaper hospital costs as well, alongside ease of use and care spreads. The costs of deploying the kind of marketing manpower to achieve this has been high but there is now an expectation the company will be profitable sometime in 2024. The share price vs revenue growth story is out of sync. It is a cheap buy. . Feel free to argue concerns in an informed way, otherwise try therapeutic tactics to avoid nonsensical posts as that looks like baiting.